Fifty 1 Labs and UAV Corp Announce AI-Driven Strategy for NASDAQ Uplisting

Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) have announced a bold AI-driven strategy aimed at reaching a $50 million valuation and securing a NASDAQ uplisting by Q1 2026. This initiative includes a $1 million R&D effort to discover repurposed treatments by May 2026, the launch of a digital platform by July 31, 2025, and the pursuit of biotech acquisitions valued between $5–10 million. Supported by a $350,000 insider investment and leadership salary deferrals, the company is poised to make significant strides in the functional medicine market, which is valued at $320.6 billion. With a leadership team that includes Nobel laureate Dr. James Orbinski and NFL veteran Brandon Spikes, Fifty 1 Labs is focusing on personalized AI-powered healthcare solutions to disrupt the industry.

The company's subsidiary, Fifty1 AI Labs LLC, is at the forefront of this strategy, with plans to host a shareholder event in Q3 2025 to showcase progress and future directions. This move underscores Fifty 1 Labs' commitment to innovation in health, wellness, and biotechnology, leveraging its wholly owned subsidiaries, including Genetic Networks LLC, to accelerate drug discovery and enhance athletic performance and recovery through its sports nutrition line.